Darifenacin is a muscarinic M₃ receptor antagonist used to treat overactive bladder (OAB) with symptoms such as urge urinary incontinence, urgency, and frequency. By selectively blocking M₃ receptors in the bladder's detrusor muscle, darifenacin reduces involuntary contractions, improving bladder control and storage capacity.
It is administered orally, typically as an extended-release tablet, allowing for once-daily dosing.
Indications include:
∙ Overactive bladder (OAB) with symptoms of:
o Urinary urgency
o Urge incontinence
o Increased urinary frequency
Parent: Darifenacin
Parent: Darifenacin
Parent: Darifenacin
Parent: Darifenacin
Parent: Darifenacin
Parent: Darifenacin
Parent: Darifenacin
Parent: Darifenacin
Parent: Darifenacin
Parent: Darifenacin
Impurities in darifenacin arise from its multi-step synthesis, which includes formation of isoindoline, quinuclidine, and aryl ether intermediates, and from degradation under oxidative or hydrolytic conditions. As it is used chronically in older adults, impurity limits must comply with ICH Q3A/B and USP/EP requirements.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Darifenacin is used to treat overactive bladder, helping to reduce urinary urgency, frequency, and urge incontinence by relaxing bladder muscles.
It selectively blocks M₃ muscarinic receptors in the bladder, which are responsible for involuntary muscle contractions that lead to urgency and incontinence.
Darifenacin’s M₃-selectivity may reduce some side effects (like confusion or cardiac effects) compared to non-selective antimuscarinics, but it can still cause dry mouth and constipation.
Yes, darifenacin is generally stable under standard storage conditions but may degrade with excessive heat, moisture, or light. It should be stored in a cool, dry place in its original container.
